ESMO 2016

Atezolizumab Improves Overall Survival Versus Docetaxel in NSCLC

Atezolizumab Improves Overall Survival Versus Docetaxel in NSCLC

By

Treatment with atezolizumab resulted in a statistically significant and clinically relevant improvement in overall survival.

Full-dose Neoadjuvant Anthracycline + Ifosfamide Improves OS in High-risk Soft Tissue Sarcoma

Full-dose Neoadjuvant Anthracycline + Ifosfamide Improves OS in High-risk Soft Tissue Sarcoma

By

Treatment with a full-dose regimen consisting of an anthracycline plus ifosfamide administered for 3 courses prior to surgery improves relapse-free and overall survival.

First-line Nivolumab Not Superior to Chemo for Stage IV/Recurrent PD-L1+ NSCLC

First-line Nivolumab Not Superior to Chemo for Stage IV/Recurrent PD-L1+ NSCLC

By

First-line treatment with nivolumab was not superior to investigator's choice of platinum-based doublet chemotherapy for progression-free survival.

Adding Ribociclib to Letrozole Improves PFS in HR+ Advanced Breast Cancer

Adding Ribociclib to Letrozole Improves PFS in HR+ Advanced Breast Cancer

By

Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.

Adjuvant Ipilimumab Improves OS in High-risk Stage III Melanoma

Adjuvant Ipilimumab Improves OS in High-risk Stage III Melanoma

By

Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

By

Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.

Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

By

Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer.

Nivolumab Feasible for Early Stage Resectable NSCLC

Nivolumab Feasible for Early Stage Resectable NSCLC

By

Study findings suggest that anti-PD1 immunotherapy may have significant activity among patients with early stage NSCLC.

Study Explores Efficacy of Fosaprepitant Regimen Among Patients Receiving MEC

Study Explores Efficacy of Fosaprepitant Regimen Among Patients Receiving MEC

By

A 1-day, 3-drug, fosaprepitant-containing regimen is efficacious for preventing chemotherapy-induced nausea and vomiting.

Durvalumab Shows Encouraging OS Rates in Advanced HNSCC

Durvalumab Shows Encouraging OS Rates in Advanced HNSCC

By

PD-L1 inhibition with durvalumab is associated with encouraging overall survival rates in pretreated HNSCC.

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

By

Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.

Abiraterone Lacks Activity in Recurrent High Grade Serous Epithelial Ovarian Cancer

Abiraterone Lacks Activity in Recurrent High Grade Serous Epithelial Ovarian Cancer

By

Further investigation is warranted to assess the activity of abiraterone among patients with low grade serous EOC.

Abemaciclib Associated With a Greater Reduction in Ki67 Than Anastrozole in Breast Cancer

Abemaciclib Associated With a Greater Reduction in Ki67 Than Anastrozole in Breast Cancer

By

Among women with HER2-negative breast cancer, treatment with abemaciclib reduced Ki67 levels more than anastrozole.

Alisertib May Benefit Some Patients With Neuroendocrine Prostate Cancer

Alisertib May Benefit Some Patients With Neuroendocrine Prostate Cancer

By

Aurora kinase A inhibition with alisertib monotherapy may benefit a subset of patients with neuroendocrine prostate cancer (NEPC).

Vandetanib Active in RET-rearranged Advanced NSCLC

Vandetanib Active in RET-rearranged Advanced NSCLC

By

Vandetanib demonstrates antitumor activity among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC).

Ceritinib Active in ALK Inhibitor-naive Patients With ALK+ NSCLC

Ceritinib Active in ALK Inhibitor-naive Patients With ALK+ NSCLC

By

Ceritinib induced robust whole body responses in anaplastic lymphoma kinase (ALK) inhibitor-naive patients with ALK-rearranged non-small cell lung cancer (NSCLC).

Adding Evofosfamide to Doxorubicin Fails to Improve OS in Sarcoma

Adding Evofosfamide to Doxorubicin Fails to Improve OS in Sarcoma

By

Among patients with advanced soft tissue sarcoma, adding evofosfamide to doxorubicin failed to improve overall survival compared with doxorubicin alone.

Trabectedin Improves PFS vs Best Supportive Care in Sarcoma

Trabectedin Improves PFS vs Best Supportive Care in Sarcoma

By

Compared with best supportive care, trabectedin significantly improves progression-free survival among patients with pretreated advanced soft tissue sarcoma.

Everolimus + Letrozole Efficacious in ER+, HER2- Advanced Breast Cancer

Everolimus + Letrozole Efficacious in ER+, HER2- Advanced Breast Cancer

By

Everolimus plus letrozole is efficacious as a first-line treatment regimen for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.

Nivolumab May Be Better Than BSC for Advanced Hepatocellular Carcinoma

Nivolumab May Be Better Than BSC for Advanced Hepatocellular Carcinoma

By

Second-line treatment with nivolumab was well tolerated and associated with encouraging preliminary activity among patients with hepatocellular carcinoma.

Daratumumab Plus Bortezomib and Dex Improves PFS, ORR in Myeloma

Daratumumab Plus Bortezomib and Dex Improves PFS, ORR in Myeloma

By

Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment.

Ipilimumab 10 mg/kg Associated With Improved OS But More AEs in Advanced Melanoma

Ipilimumab 10 mg/kg Associated With Improved OS But More AEs in Advanced Melanoma

By

In contrast with a 3 mg/kg dose, ipilimumab monotherapy at a dose of 10 mg/kg is associated with improved overall survival.

Biosimilar Equivalent to Pegfilgrastim for Chemo-induced Neutropenia Prophylaxis

Biosimilar Equivalent to Pegfilgrastim for Chemo-induced Neutropenia Prophylaxis

By

MYL-1401H is equivalent in efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia among patients with breast cancer.

Lurbinectedin Active in BRCA Mutation-positive Metastatic Breast Cancer

Lurbinectedin Active in BRCA Mutation-positive Metastatic Breast Cancer

By

Lurbinectedin induces DNA double-strand breaks, and regulates the tumor microenvironment.

Neoadjuvant CRT Improves Survival in Locally Advanced Squamous Cell Esophageal Cancer

Neoadjuvant CRT Improves Survival in Locally Advanced Squamous Cell Esophageal Cancer

By

Adding chemoradiotherapy prior to surgery improves survival versus surgery alone in patients with locally advanced esophageal squamous cell carcinoma (SCC).

Metastasis-free Survival: a Surrogate for OS in Localized Prostate Cancer

Metastasis-free Survival: a Surrogate for OS in Localized Prostate Cancer

By

Researchers can use metastasis-free survival as a surrogate end point for overall survival in clinical trials evaluating patients with localized prostate cancer.

Selinexor May Benefit Patients Ovarian or Endometrial Cancer

Selinexor May Benefit Patients Ovarian or Endometrial Cancer

By

Treatment with selinexor is active in patients with heavily pretreated patients with metastatic ovarian or endometrial cancer.

Prexasertib Shows Promising Activity in High-grade Ovarian Cancer

Prexasertib Shows Promising Activity in High-grade Ovarian Cancer

By

Prexasertib demonstrates promising activity in patients with BRCA wild type sporadic high-grade serous ovarian cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs